European Archives - Page 529 of 1054 - European Medical Journal

Was the pandemic the rebrand pharma needed?

The pharmaceutical industry has long struggled with its reputation, but 2020 offered an opportunity for reform. How has their response to the crisis affected perceptions, or is misinformation still getting in the way?

Securing patient care beyond COVID-19

While attention was channelled into COVID-19, patients awaiting other treatments were deprioritised. How can pharma ensure no patients are left behind?

Roundtable: a conversation about drug pricing

Hear from two thought leaders who share their passion for health economics, their thoughts on non-traditional models, and how they predict drugs will be costed in the future.

Can medical affairs help reduce health inequalities?

COVID-19 has revealed a pandemic of another kind: existing health inequities between population groups. We explore the role and responsibility of medical affairs teams in addressing imbalances and forging a fairer and more inclusive health landscape for the future

Finding a fast lane for precision medicine

What are the obstacles in the way of rolling out precision medicine and how can medical affairs professionals overcome them to fast-track adoption for patients?

Let's talk about sexual health

What role can medical affairs professionals play in filling this knowledge gap as they communicate the importance of sexual health?

Is pharma ready to stop cyber attacks in their tracks?

Cyber-attacks have become a mounting threat to the pharmaceutical industry over the past year, putting COVID-19 research data as well as supply and distribution chains at risk. We explore what can pharma learn from more experienced industries as they try to mitigate hacking

Abbott Vascular’s Nick West on powering up personalised care

Dr Nick West, Chief Medical Officer, Abbott Vascular, shares with GOLD his hopes for the future of personalised care, enhancing patient centricity worldwide and the upskilling potential of virtual reality.

EMJ Dermatology 9 [Supplement 3] 2021 Feature Image

Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab

The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…

EMJ Dermatology 9 [Supplement 3] 2021 Feature Image

EMJ Dermatology 9 [Supplement 3] 2021

In this supplement to EMJ Dermatology, two leading dermatologists, Dr Sascha Gerdes and Dr Julia-Tatjana Maul, explored the use of IL-23…